SEC Comment Letter for Entero Therapeutics, Inc. (GRDX) (CIK 0001604191) (GRDX) — May 6, 2019

Entero Therapeutics, Inc. (GRDX) (CIK 0001604191)
Date: May 6, 2019 · CIK: 0001604191 · Accession: 0000000000-19-008070

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-231035

Date

May 6, 2019

Author

Dorrie Yale

Form

UPLOAD

Company

Entero Therapeutics, Inc. (GRDX) (CIK 0001604191)

Letter

May 6, 2019 Johan Spoor President and Chief Executive Officer AzurRx BioPharma, Inc. 760 Parkside Avenue Downstate Biotechnology Incubator, Suite 304 Brooklyn, NY 11226 Re:AzurRx BioPharma, Inc. Registration Statement on Form S-3 Filed April 26, 2019 File No. 333-231035 Dear Mr. Spoor: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dorrie Yale at 202-551-8776 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Jessica R. Sudweeks - Disclosure Law Group

Show Raw Text

May 6, 2019
Johan Spoor
President and Chief Executive Officer
AzurRx BioPharma, Inc.
760 Parkside Avenue
Downstate Biotechnology Incubator, Suite 304
Brooklyn, NY 11226
Re:AzurRx BioPharma, Inc.
Registration Statement on Form S-3
Filed April 26, 2019
File No. 333-231035
Dear Mr. Spoor:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Dorrie Yale at 202-551-8776 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc:       Jessica R. Sudweeks - Disclosure Law Group

SecProbe.io